Technical analysis of KalVista Pharmaceuticals, Inc. (KALV): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +67.18% |
| 1 year | +101.79% |
| 3 years | +175.51% |
| 5 years | +40.26% |
52-Week Range
| 52-week High | $27.00 |
| 52-week Low | $9.83 |
| Avg Volume (90d) | 2.7M |
Technical Indicators
| SMA 50 | $24.29 |
| SMA 200 | $16.98 |
| Beta | -0.40 |
| 30-day Volatility (annualised) | 1.9% |
| Price vs SMA 50 | +11.1% |
| Price vs SMA 200 | +59.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $10.91 | |
| 2025-11 | $14.47 | +32.6% |
| 2025-12 | $16.15 | +11.6% |
| 2026-01 | $15.61 | -3.3% |
| 2026-02 | $16.28 | +4.3% |
| 2026-03 | $20.13 | +23.6% |
| 2026-04 | $26.66 | +32.4% |
| 2026-05 | $26.87 | +0.8% |
| 2026-06 | $27.00 | +0.5% |
Price
| Price | $27.00 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -503.31 |
| EV / EBITDA | -12.74 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -104.83 |
| Current Ratio | 5.58 |